What weight loss supplement was pulled by fda in 2000
Saxenda (liraglutide), from Novo Nordisk is a glucagon-like peptide-1 (GLP-1) analogue for the treatment of obesity and was FDA-approved in 2014 for weight-loss due to obesity. It is given as a subcutaneous (under the skin) injection once a day and is used in addition to diet and exercise.